{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:02:23Z","timestamp":1789794143330,"version":"4.0.1"},"reference-count":28,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.26-0221","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:11:52Z","timestamp":1789769512000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Pathological Complete Response after Conversion Surgery for Distal Cholangiocarcinoma with High Tumor Mutational Burden and Para-Aortic Lymph Node Metastasis: A Case Report"],"prefix":"10.70352","volume":"12","author":[{"given":"Ken","family":"Hatano","sequence":"first","affiliation":[{"name":"Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gensho","family":"Tanke","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Uryuhara","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kaihara","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet 2021; 397: 428\u201344.","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657\u201369.","DOI":"10.1136\/gutjnl-2011-301748"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Nagino M. Fifty-year history of biliary surgery. Ann Gastroenterol Surg 2019; 3: 598\u2013605.","DOI":"10.1002\/ags3.12289"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1: EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401: 1853\u201365.","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ioka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci 2023; 30: 102\u201310.","DOI":"10.1002\/jhbp.1219"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Stenzinger A, Allen JD, Maas J, et al. Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer 2019; 58: 578\u201388.","DOI":"10.1002\/gcc.22733"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 2019; 30: 44\u201356.","DOI":"10.1093\/annonc\/mdy495"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Shao C, Li G, Huang L, et al. Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw Open 2020; 3: e2025109.","DOI":"10.1001\/jamanetworkopen.2020.25109"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020; 21: 1353\u201365.","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Zhou Y, Wang Q, Lin M, et al. Survival benefit of conversion surgery for initially unresectable biliary tract cancer: a systematic review and meta-analysis. Langenbecks Arch Surg 2025; 410: 63.","DOI":"10.1007\/s00423-025-03630-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Arita J, Ichida A, Nagata R, et al. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors. J Hepatobiliary Pancreat Sci 2022; 29: 732\u201340.","DOI":"10.1002\/jhbp.1135"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Satoi S, Yamamoto T, Yamaki S, et al. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2020; 4: 6\u201313.","DOI":"10.1002\/ags3.12295"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nitta N, Ohgi K, Sugiura T, et al. Prognostic impact of paraaortic lymph node metastasis in extrahepatic cholangiocarcinoma. World J Surg 2021; 45: 581\u20139.","DOI":"10.1007\/s00268-020-05834-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Gundavda K, Chopde A, Pujari A, et al. Prognostic Impact of Para-Aortic Lymph Node Metastasis in Resected Non-Pancreatic Periampullary Cancers. Ann Surg Oncol 2024; 31: 7052\u201363.","DOI":"10.1245\/s10434-024-15847-z"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273\u201381.","DOI":"10.1056\/NEJMoa0908721"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Ushida Y, Inoue Y, Oba A, et al. Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: a single-center retrospective study. Ann Surg Oncol 2022; 29: 5038\u201350.","DOI":"10.1245\/s10434-022-11503-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Satoi S, Yamaue H, Kato K, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013; 20: 590\u2013600.","DOI":"10.1007\/s00534-013-0616-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to pd-1 inhibition. N Engl J Med 2017; 377: 2500\u20131.","DOI":"10.1056\/NEJMc1713444"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Aggarwal C, Ben-Shachar R, Gao Y, et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw Open 2023; 6: e2311181.","DOI":"10.1001\/jamanetworkopen.2023.11181"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Dekker EN, van Dam JL, Janssen QP, et al. Improved clinical staging system for localized pancreatic cancer using the abc factors: a taps consortium study. J Clin Oncol 2024; 42: 1357\u201367.","DOI":"10.1200\/JCO.23.01311"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Nakamura I, Hatano E, Baba H, et al. Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer. Ann Gastroenterol Surg 2023; 7: 1009\u201320.","DOI":"10.1002\/ags3.12713"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Wang S, Wang Y, Zhu C, et al. Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1\/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study. Int J Surg 2024; 110: 4608\u201316.","DOI":"10.1097\/JS9.0000000000001540"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Yabushita Y, Park JS, Yoon YS, et al. Conversion surgery for initially unresectable locally advanced biliary tract cancer: a multicenter collaborative study conducted in Japan and Korea. J Hepatobiliary Pancreat Sci 2024; 31: 481\u201391.","DOI":"10.1002\/jhbp.1437"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Chen K, Feng X, Shi Y, et al. Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: a case report and review of literature. World J Gastrointest Oncol 2025; 17: 98433.","DOI":"10.4251\/wjgo.v17.i1.98433"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Zeng ZX, Wu JY, Zhang ZB, et al. Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery. Liver Cancer 2024; 13: 498\u2013508.","DOI":"10.1159\/000536376"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Nakayama T, Nakano H, Matsushita R, et al. Pathological complete response after chemotherapy in initially unresectable distal cholangiocarcinoma. Clin J Gastroenterol 2025; 18: 357\u201362.","DOI":"10.1007\/s12328-024-02084-w"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 2023; 401: 195\u2013203.","DOI":"10.1016\/S0140-6736(22)02038-4"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0221\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:24:49Z","timestamp":1789791889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0221\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.26-0221","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.26-0221"}}